Navigation Links
Arno Therapeutics to Present Positive, New Data Supporting the Potential of Onapristone in Endometrial and Breast Cancers at ASCO 2013 Annual Meeting
Date:5/15/2013

FLEMINGTON, N.J., May 15, 2013 /PRNewswire/ -- Arno Therapeutics, Inc. (OTCQB: ARNI), a clinical stage biopharmaceutical company focused on the development of oncology therapeutics, today announced new, positive data from three studies supporting its investigational compound onapristone to be presented at the American Society of Clinical Oncology (ASCO) 2013 Annual Meeting, which is being held May 31-June 4, 2013 in Chicago, Illinois.

Three separate preclinical studies support further investigation of onapristone - an orally-administered, investigational type 1 progestin receptor antagonist - and the development of a diagnostic test for the compound to identify patients with activated progesterone receptor (APR) as a potential biomarker of anti-progestin activity in endometrial and breast cancers.  Recently, Arno Therapeutics announced its collaboration with Clarient Diagnostic Services Inc., a GE healthcare company, and leading provider of cancer diagnostic testing, to develop a diagnostic test to identify cancerous tumors with APR.

Onapristone is believed to work by binding to a protein called the progesterone receptor, thereby inhibiting dimerization, phosphorylation and DNA transcription activity. Progesterone receptors (PRs) are found in particular cells including those of the female reproductive tissue and some cancers.[i] The hormone progesterone binds to the receptors and may cause the cells to grow.i  Preclinical studies have shown that PRs can play a role as drivers of malignant cell growth in certain cancers."We are pleased with the findings as they support the development of a diagnostic test for onapristone to help identify patients with activated progesterone receptors in endometrial and breast cancers who are most likely to benefit from treatment in these difficult-to-treat diseases," said Glenn Mattes , chief executive officer
'/>"/>

SOURCE Arno Therapeutics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Cell Therapeutics, Inc. (CTI) to Report First Quarter Financial Results on April 20
2. Faruqi & Faruqi, LLP Encourages Investors Who Suffered Substantial Losses Investing in Chelsea Therapeutics International, Ltd. to Contact the Firm
3. Argos Therapeutics Secures $25 million Series D Financing to Commence Phase 3 ADAPT Study in Patients with Metastatic Renal Cell Carcinoma (mRCC) in Mid-2012
4. Novelos Therapeutics Announces Successful Completion of First Cohort In Lung Cancer Trial With I-124-CLR1404 (LIGHT) Cancer-Targeted PET Imaging Agent at UW Carbone Cancer Center
5. Zacks Industry Outlook Highlights: Eli Lilly, Forest Labs, ViroPharma, Novartis and United Therapeutics
6. Oxford BioTherapeutics Appoints Senior Industry Leader to Head its New Clinical Development Operations in Basel, Switzerland
7. Nektar Therapeutics Reports Financial Results for the First Quarter of 2012
8. Cara Therapeutics Licenses Novel Kappa Opioid Agonist, CR845, to Chong Kun Dang Pharmaceutical Corporation For South Korean Market
9. Frost & Sullivan: High Uptake of New Drug Therapies and Aging Population Expansion Keep the U.S. Retinal Therapeutics Market Buoyant
10. Zenobia Therapeutics, Inc. And BioBlocks, Inc. Announce Sale Of A Joint Fragment Library Ideal For Screening By All Popular Methods
11. New Forecast Shows Global Protein Therapeutics Market to Reach $143.4 Billion by 2015
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... Jan. 15, 2014  Celsion Corporation (the "Company") (NASDAQ: ... from institutional investors to purchase an aggregate of approximately ... at-the-market registered direct offering, led by a dedicated health ... purchase agreements with these investors pursuant to which the ...
(Date:1/15/2014)... Shire plc (LSE: SHP, NASDAQ: SHPG ) announces that ... to the announced tender offer for all of the outstanding shares ... of the waiver, the transaction is no longer conditional on OFT ... 24, 2014 following the currently scheduled expiration time, subject to the ...
(Date:1/15/2014)... 15, 2014 BreedIT Corp (OTC: BRDT), ... distributor of highly sophisticated agro-breeding solutions for plant breeders ... the Company,s board of directors appointed chemistry and pharmaceutical ... new member of the board. From 1975 ...
Breaking Medicine Technology:Celsion Corporation Announces $15 Million At-The-Market Registered Direct Offering 2Celsion Corporation Announces $15 Million At-The-Market Registered Direct Offering 3Shire Waives OFT Condition Relating to the Acquisition of ViroPharma Inc. 2Shire Waives OFT Condition Relating to the Acquisition of ViroPharma Inc. 3BreedIT (OTC: BRDT) Appoints Chemistry and Pharmaceutical Industry Expert Dr. Ben-Zion Weiner to Its Board of Directors 2BreedIT (OTC: BRDT) Appoints Chemistry and Pharmaceutical Industry Expert Dr. Ben-Zion Weiner to Its Board of Directors 3
... LAKE CITY, Jan. 28, 2011 TechniScan (OTC Bulletin ... engaged in the development and commercialization of an automated ... Robinson, Chief Executive Officer, will present at RetailInvestorConferences.com. DATE: ... ESTLINK: , www.retailinvestorconferences.com This will be a live, ...
... BioSciences, Inc. (NasdaqCM: DARA), a biopharmaceutical development company ... through proof of concept in humans for subsequent ... today that Richard Franco, CEO, will present at ... 5:00 PM ESTLINK: , www.retailinvestorconferences.com This will ...
Cached Medicine Technology:TechniScan to Present Live, Online at RetailInvestorConferences.com on February 3rd 2DARA BioSciences to Present Live at RetailInvestorConferences.com on February 3 2DARA BioSciences to Present Live at RetailInvestorConferences.com on February 3 3
(Date:4/17/2014)... created a new technology for modifying human cells ... body and selectively target cancer and other sites ... monitor and modify human physiology is a promising ... technology enabled bioengineers to build such devices that ... a customized fashion. , "The project addressed a ...
(Date:4/17/2014)... NEW YORK, NY (April 16, 2014) The cause ... but a new study proposes that neurons may be ... own immune system, similar to the way autoimmune diseases ... attack the body,s cells. The study was published April ... is a new, and likely controversial, idea in Parkinson,s ...
(Date:4/17/2014)... EcoHealth Alliance, a nonprofit organization that focuses on conservation ... today examining the current state of knowledge of the ... improved global surveillance strategies to combat the emergence of ... in West Africa that has claimed the lives of ... According to the World Health Organization (WHO), the ...
(Date:4/17/2014)... YORK (17 April 2014) Population Council scientists and their ... safe, stable, and can prevent the transmission of multiple ... rectum in animals: HIV, herpes simplex virus 2 (HSV-2), ... the first data that the gel is effective against ... efficacy in the vagina against all three viruses of ...
(Date:4/17/2014)... is less than 40 years away from a food ... governments, according to a top scientist at the U.S. ... human history, food production will be limited on a ... energy," said Dr. Fred Davies, senior science advisor for ... become as politically destabilizing by 2050 as energy issues ...
Breaking Medicine News(10 mins):Health News:Building 'smart' cell-based therapies 2Health News:Is Parkinson's an autoimmune disease? 2Health News:Re-emergence of Ebola focuses need for global surveillance strategies 2Health News:Re-emergence of Ebola focuses need for global surveillance strategies 3Health News:Animal study provides first evidence that gel can prevent multiple virus transmission in vagina/rectum 2Health News:Food shortages could be most critical world issue by mid-century 2
... government of India.,Clearly positing development against environment, it has asked ... that sits over environmental issues. ,Seeking the vacation ... (FAC), constituted under the Forest Conservation Act, the federal government ... on the ground that it has outlived its utility and ...
... Sir Paul McCartney has offered 20 million pounds to his ... is adamantly demanding 50 million pounds, if reports are ... the couple settled their matter in the range of somewhere ... of estimated 825 million pounds. ,However, their stubbornness ...
... on the Chinese Government to introduce strict regulations to ... summer and winter holiday periods. ,Shang Xiyun ... hearing her eight-year-old daughter declare that she would never ... watching a TV ad for underwear featuring a half-naked ...
... have developed a mathematical model that identifies genes that battle ... ,Researchers conducted a joint study led Dr. Milton Taylor, ... of Evolution of the University of Haifa. ,The ... have had a blood transfusion or who share needles, attacks ...
... found that blood transfusion from donors with undiagnosed cancers ... malignant disease than individuals who receive blood from ... carry out a rigorous battery of tests before the ... diseases are passed between the donor and recipient. Although ...
... the planet, sending automakers back to the drawing board to develop ... ,"There is no doubt that 10 years down ... the planet is going to be higher," said Ghosn, who heads ... ,"The average consumer on earth is going to be much ...
Cached Medicine News:Health News:Indian Government Asks the Supreme Court to Keep Off Environmental Issues 2Health News:Indian Government Asks the Supreme Court to Keep Off Environmental Issues 3Health News:Indian Government Asks the Supreme Court to Keep Off Environmental Issues 4Health News:Blood Transfusions Does Not Increase the Risk of Cancer Transmission 2Health News:Motorists Getting Greyer, Greener, Thriftier: Nissan's Ghosn 2
Proven and Efficient Stand-Alone Device. Offers a choice between alternate breath and every breath delivery. This model provides alternate breath delivery....
... An All-In-One Conserver., ,Offers an average 5:1 ... ,Allows the use of a standard cannula. ... and lightweight cylinders offers ambulatory oxygen patients a ... backed by a 2-year warranty. ...
... ,Offers an average 5:1 increase in usage ... use of a standard cannula. , ,The ... offers ambulatory oxygen patients a superior alternative to ... 2-year warranty. , ...
... Conserver., ,Offers an average 5:1 increase in ... the use of a standard cannula. , ... cylinders offers ambulatory oxygen patients a superior alternative ... a 2-year warranty. , ...
Medicine Products: